The Research Animal Support Facility (RASF) has been a shared resource since the original CCSG wasawarded in 1975 and exists to support ongoing clinical and basic cancer research involving laboratoryanimals at MDACC. The RASF has components located in Houston at MDACC (2 campuses), and inSmithville in the Department of Carcinogenesis. All animal facilities are accredited by the Association for theAssessment and Accreditation of Laboratory Animal Care International, have Animal Welfare Assuranceapproval (A3343-01), and are registered as research animal facilities with the United States Department ofAgriculture (USDA) (74-R-065). The Research Animal Support Facility Houston (RASFH) is directed byPeggy T. Tinkey, D.V.M. The RASFH encompasses approximately 99,089 sq. ft. of space and provideshousing, procedure space, veterinary care, and quality assurance programs for animals used in cancerresearch. Clinical, surgical, imaging, radiation therapy, and pathology laboratory facilities and services areprovided. Existing technical services have been extended to the South Campus facility, and new servicesadded since the last CCSG renewal include computerized animal pedigree and medical history applications,preclinical toxicology services, and increased transportation services. New equipment includes automatedmulti-species hematology and chemistry analyzers, patient monitoring systems, automated beddingdispensing systems and waste containers, cargo van, and 100 ventilated rodent rack/cage systems. TheRASFH has 122 personnel, which includes 11 veterinarians, 2 associate directors, 1 administrator, 2 sectionmanagers, 1 project manager, 10 laboratory personnel, 77 animal care personnel, and 17 clerical/supportstaff. Dr. Tinkey coordinates the daily operations of the RASFH. Five faculty veterinarians direct the 5service sections that provide facilities, equipment, and services to research animal users. Funding for theRASFH is currently provided by the CCSG (6%), user fees (39%), institutional support (53%) and other funds(2%). In the past 5 years, the RASFH has been used by 319 investigators supporting 20 different CCSGprograms. Peer-reviewed investigators represent 92% of the RASFH user utilization. The majority ofanimals used are genetically engineered mice. In the past 5 years, the daily average cage counts increased52%, from 13,243 cages in 2002-03 to 20,132 cages of animals in 2006-07. Future plans include renovationand expansion of the South Campus animal facility, and upgrading and implementing computer applicationsfor business operations and preclinical drug development. Additionally, RASF-Houston and Smithville havejointly submitted a startup proposal to develop a Mutant Mouse Pathology Service to serve all MDACCinvestigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016672-33
Application #
7695934
Study Section
Subcommittee G - Education (NCI)
Project Start
2008-08-28
Project End
2013-06-30
Budget Start
2008-08-28
Budget End
2009-06-30
Support Year
33
Fiscal Year
2008
Total Cost
$819,948
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Yu, Yao; Hu, Hao; Chen, Jiun-Sheng et al. (2018) Integrated case-control and somatic-germline interaction analyses of melanoma susceptibility genes. Biochim Biophys Acta Mol Basis Dis 1864:2247-2254
Melancon, Marites P; Appleton Figueira, Tomas; Fuentes, David T et al. (2018) Development of an Electroporation and Nanoparticle-based Therapeutic Platform for Bone Metastases. Radiology 286:149-157
Zhao, Hui; Zhang, Ning; Ho, Vivian et al. (2018) Adherence to treatment guidelines and survival for older patients with stage II or III colon cancer in Texas from 2001 through 2011. Cancer 124:679-687
Pan, Hubert Y; Jiang, Jing; Hoffman, Karen E et al. (2018) Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. J Clin Oncol 36:1823-1830
Grossberg, Aaron J; Mohamed, Abdallah S R; Elhalawani, Hesham et al. (2018) Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. Sci Data 5:180173
Lu, Zhimin; Hunter, Tony (2018) Metabolic Kinases Moonlighting as Protein Kinases. Trends Biochem Sci 43:301-310
Beadnell, Thomas C; Nassar, Kelsey W; Rose, Madison M et al. (2018) Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer. Oncogenesis 7:23
Chen, Xiuhui; Mangala, Lingegowda S; Rodriguez-Aguayo, Cristian et al. (2018) RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev 37:107-124
Kono, Miho; Fujii, Takeo; Matsuda, Naoko et al. (2018) Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis. J Cancer 9:3640-3646
Khouri, Issa F; Fernandez Curbelo, Irina; Turturro, Francesco et al. (2018) Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clin Cancer Res 24:1011-1018

Showing the most recent 10 out of 12418 publications